| scholarly article | Q13442814 |
| P2093 | author name string | Shao-Chun Wang | |
| Burkhard Göke | |||
| Christiane Bruns | |||
| Antonia Rizzani | |||
| Eike Gallmeier | |||
| Enrico N De Toni | |||
| Tomas Hucl | |||
| Helga-Paula Török | |||
| Andreas Ziesch | |||
| Sandra Hocke | |||
| Shuai Lü | |||
| P2860 | cites work | Susceptibility pathways in Fanconi's anemia and breast cancer | Q24628760 |
| The mechanism of necroptosis in normal and cancer cells | Q27005878 | ||
| In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor | Q27824848 | ||
| Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer | Q27851614 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival | Q28188554 | ||
| Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors | Q28190640 | ||
| Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer | Q28260207 | ||
| The intersection between DNA damage response and cell death pathways | Q28611423 | ||
| Expanded roles of the Fanconi anemia pathway in preserving genomic stability | Q28749668 | ||
| Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
| A syngeneic variance library for functional annotation of human variation: application to BRCA2 | Q33348194 | ||
| Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) | Q33906524 | ||
| Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. | Q34006269 | ||
| Microsatellite Instability, KRAS Mutations and Cellular Distribution of TRAIL-Receptors in Early Stage Colorectal Cancer | Q34532108 | ||
| Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery | Q34608366 | ||
| Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. | Q35049271 | ||
| Functional defects in the fanconi anemia pathway in pancreatic cancer cells | Q35102998 | ||
| BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure | Q35886872 | ||
| The Fanconi Anemia/BRCA pathway: new faces in the crowd | Q36343120 | ||
| Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models | Q36697991 | ||
| Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials | Q36849203 | ||
| Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | Q36938811 | ||
| Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations | Q37011738 | ||
| Regulation of DNA repair throughout the cell cycle | Q37088926 | ||
| Death receptors as targets for anti-cancer therapy | Q37390893 | ||
| The contribution of BRCA1 and BRCA2 to ovarian cancer | Q37453854 | ||
| Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature | Q37477967 | ||
| Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation | Q37784920 | ||
| DNA Repair: Exploiting the Fanconi Anemia Pathway As a Potential Therapeutic Target | Q37852698 | ||
| Targeting extrinsic apoptosis in cancer: Challenges and opportunities | Q38330808 | ||
| Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. | Q39297108 | ||
| TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. | Q39720687 | ||
| Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma | Q39831266 | ||
| OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer | Q39954498 | ||
| Disruption of the FA/BRCA pathway in bladder cancer | Q40052370 | ||
| Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer | Q40154042 | ||
| Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options | Q40269894 | ||
| Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition | Q40388302 | ||
| Inhibition of cancer cell growth by BRCA2. | Q40745331 | ||
| Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas | Q41148624 | ||
| Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer | Q42461070 | ||
| Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy | Q42733519 | ||
| Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells | Q42874678 | ||
| Population genetics of BRCA1 and BRCA2. | Q43109039 | ||
| Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice | Q43860748 | ||
| Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients | Q44314670 | ||
| Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors | Q46326788 | ||
| Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation | Q46602952 | ||
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
| Fanconi anemia gene mutations in young-onset pancreatic cancer | Q73400804 | ||
| High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells | Q79856311 | ||
| Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families | Q93945614 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9477-9490 | |
| P577 | publication date | 2016-01-28 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis | |
| P478 | volume | 7 |
| Q91620888 | Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer | cites work | P2860 |
Search more.